The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level

Overview

Journal Intern Med

Specialty General Medicine

Date 2017 Nov 3

PMID 29093381

Citations 8

Authors

Takeshi Osawa

Kozo Morimoto

Yuka Sasaki

Shuichi Matsuda

Kazunari Yamana

Ryozo Yano

Takashi Uchiyama

Hajime Goto

Affiliations

Soon will be listed here.

Abstract

We report the case of a 61-year-old woman with rapidly progressive interstitial lung disease caused by clinically amyopathic dermatomyositis. Both the serum ferritin and anti-melanoma differentiation-associated gene 5 (MDA5) antibody levels were elevated at the time of admission. Despite intensive treatment with corticosteroids, immunosuppressants, immunoglobulins and polymyxin B direct hemoperfusion, the patient died 75 days after symptom onset. Over the course of treatment, the anti-MDA5 antibody level continually decreased, while the serum ferritin level increased, suggesting that sequential measurements of the serum ferritin level might be useful for evaluating the treatment responsivity, irrespective of the anti-MDA5 antibody level.

Citing Articles

Clinical Characteristics and Outcomes of Patients with Anti-MDA5 Antibody Associated Rapidly Progressive Interstitial Lung Disease (RP-ILD): A Case Series.

Gangadharan H, Seetha A, Musthafa S, Shenoy P, Francis M, Krishna A Mediterr J Rheumatol. 2025; 35(4):668-679.

PMID: 39886293 PMC: 11778606. DOI: 10.31138/mjr.020324.cco.

FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.

Kastrati K, Nakuz T, Kulterer O, Gessl I, Simader E, Mrak D EClinicalMedicine. 2024; 72:102598.

PMID: 38633577 PMC: 11019096. DOI: 10.1016/j.eclinm.2024.102598.

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies.

Nombel A, Fabien N, Coutant F Front Immunol. 2021; 12:773352.

PMID: 34745149 PMC: 8564476. DOI: 10.3389/fimmu.2021.773352.

: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.

Conca W, Weheba I, Abouzied M, Abdelsayed A, Aleyouni Y, Al-Mutairy E Front Pharmacol. 2021; 11:585761.

PMID: 33384600 PMC: 7770219. DOI: 10.3389/fphar.2020.585761.

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.

Romero-Bueno F, Diaz Del Campo P, Trallero-Araguas E, Ruiz-Rodriguez J, Castellvi I, Rodriguez-Nieto M Semin Arthritis Rheum. 2020; 50(4):776-790.

PMID: 32534273 PMC: 11616672. DOI: 10.1016/j.semarthrit.2020.03.007.

References

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K . Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(9):1713-9. DOI: 10.1093/rheumatology/keq149. View

Gerami P, Schope J, McDonald L, Walling H, Sontheimer R . A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006; 54(4):597-613. DOI: 10.1016/j.jaad.2005.10.041. View

Oishi K, Mimura-Kimura Y, Miyasho T, Aoe K, Ogata Y, Katayama H . Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2012; 61(1):84-9. DOI: 10.1016/j.cyto.2012.08.032. View

Zou J, Li T, Huang X, Chen S, Guo Q, Bao C . Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014; 73(8):1591-3. DOI: 10.1136/annrheumdis-2014-205278. View

Yamaoka T, Doi C, Yokomi A, Tanemura A, Murota H, Tani M . Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer. Eur J Dermatol. 2014; 24(4):490-1. DOI: 10.1684/ejd.2014.2381. View

Abe S, Hayashi H, Seo Y, Matsuda K, Kamio K, Saito Y . Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011; 32(4):310-6. DOI: 10.1159/000330325. View

Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M . Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2010; 21(2):223-7. DOI: 10.1007/s10165-010-0371-x. View

Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y . Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014; 9(6):e98824. PMC: 4048238. DOI: 10.1371/journal.pone.0098824. View

Ichiyasu H, Sakamoto Y, Yoshida C, Sakamoto K, Fujita R, Nakayama G . Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column.... Respir Med Case Rep. 2016; 20:51-54. PMC: 5153447. DOI: 10.1016/j.rmcr.2016.11.015. View

10.

Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M . Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(7):1354-60. DOI: 10.1093/rheumatology/keq073. View

11.

Nakashima R, Mimori T . [Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi. 2013; 36(2):71-6. DOI: 10.2177/jsci.36.71. View

12.

Ichiyasu H, Horio Y, Tsumura S, Hirosako S, Sakamoto Y, Sakata S . Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol. 2014; 24(2):361-5. DOI: 10.3109/14397595.2013.852847. View

13.

Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M . Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest. 2013; 144(6):1934-1936. DOI: 10.1378/chest.13-0186. View

14.

Tamai K, Tachikawa R, Otsuka K, Ueda H, Hosono Y, Tomii K . Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms. Intern Med. 2014; 53(21):2515-9. DOI: 10.2169/internalmedicine.53.2769. View

15.

Abe S, Seo Y, Hayashi H, Matsuda K, Usuki J, Azuma A . Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif. 2010; 29(4):321-6. DOI: 10.1159/000287232. View

16.

Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y . Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012; 51(9):1563-70. DOI: 10.1093/rheumatology/kes102. View

17.

Sontheimer R . Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002; 46(4):626-36. DOI: 10.1067/mjd.2002.120621. View

18.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T . Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52(5):1571-6. DOI: 10.1002/art.21023. View

19.

Sato S, Kuwana M, Fujita T, Suzuki Y . Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2011; 22(4):625-9. DOI: 10.1007/s10165-011-0558-9. View

20.

Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M . A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2015; 27(3):536-540. DOI: 10.3109/14397595.2015.1014140. View